Chemed Corporation Surges 12% on Earnings Beat and Raised Guidance
NEW YORK, April 25 —
Chemed Corporation (CHE) jumped roughly 12% after beating Q1 estimates, raising full-year guidance, and buying two Roto-Rooter franchises.
- Q1 EPS and revenue both topped consensus, prompting a full-year 2026 guidance raise
- At $421.11 and 15.8x forward P/E, Chemed trades at a premium for what is partly a plumbing company
- Watch VITAS admissions growth and Roto-Rooter marketing costs when Q2 results land
What Actually Happened
Chemed is two businesses bolted together: VITAS, one of the largest hospice providers in the U.S., and Roto-Rooter, the plumbing and drain cleaning franchise. This quarter, VITAS carried the load. Hospice admissions growth drove the revenue beat, while Roto-Rooter held steady despite rising marketing costs eating into margins.
The franchise acquisitions are worth noting for what they signal. Chemed bought two Roto-Rooter franchises serving 3.3 million people, folding independent operators back into the corporate system. This is the playbook: buy back franchises, capture the full margin instead of collecting royalties. It's a slow, quiet form of consolidation that doesn't make headlines but compounds over years.
Management felt confident enough to raise full-year guidance, which is the real reason the stock popped 12%. A Q1 beat alone wouldn't do that. The guidance raise tells you they see the hospice tailwind holding through the year.
The Catch
Roto-Rooter's marketing cost pressure is the number to interrogate. The plumbing business competes for local search clicks against every independent operator with a Google Ads budget. Customer acquisition costs in home services have been climbing industry-wide, and Roto-Rooter isn't immune. If VITAS ever has a soft quarter, that margin compression on the plumbing side becomes the whole story.
There's also the valuation question. At 15.8x forward earnings and $2.5bn in TTM revenue, Chemed isn't cheap for a company where half the business is sending trucks to unclog drains. Investors are paying a hospice multiple for the whole entity. That's fine when VITAS is accelerating. Less fine if admissions growth slows.
Bottom Line
This is a clean quarter from a well-run, boring company. The combination of an earnings beat, raised guidance, and accretive acquisitions is exactly what long-term holders want to see. Chemed won't double in a year, but it grinds higher when both segments execute. The stock is more interesting after this print, particularly for investors who want healthcare exposure without biotech risk.
The number to watch next quarter: VITAS admissions growth rate. That's the engine. Everything else is plumbing.
There's no existing deep-dive report for Chemed. Generate a full Chemed (CHE) report here to see the complete financial picture.
Basis Report does not hold positions in securities discussed. This is not investment advice.